Sana Biotechnology trades at a steep discount despite promising T1D assets UP421 and SC451. Check out why SANA stock is a buy ...
Check out the most exciting updates from day 3 of Breakthrough T1D's Clinical and Research Congress focused entirely on type ...
Blood stem cells are rare cells in the bone marrow that produce the blood and immune cells needed throughout life, ensuring ...
Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward ...
A new review warns that two decades of declining pancreas transplant volumes in the United States are eroding the training ...
Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming ...
In a preliminary study of 13 patients with cancer, first-line fecal transplants resolved immunotherapy-related colitis in 10, ...
More research is needed, but experts are cautiously optimistic about the results. Patients in the trial got an experimental drug to prevent transplant rejection with fewer side effects.
Pharmaceutical & Biotech Stock Introductory Series Part 15/17]IntroductionSana Biotechnology (SANA) is a 'drug ...
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's ...
The study lasted over eleven months. All streptozotocin-induced diabetic mice administered with CNTY-813 achieved normoglycemia. CNTY-813 islets showed glucose-stimulated insulin secretion potency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results